FDA Releases Guidance on Communication with the Agency
The agency publishes draft guidance on best practices for communication between FDA and IND sponsors during drug development.
FDA released draft guidance on Dec. 4, 2015 on the agency’s recommendations for best practices in communication between investigational new drug application (IND) sponsors and FDA during drug development. The guidance provides FDA’s expectations for methods of communication and timing of FDA responses to IND sponsor inquiries. It also details the types of advice and interactions that are appropriate between IND sponsors and FDA review teams.
The guidance does not apply to communications between FDA and industry trade organizations, consumer advocacy groups, other government agencies, or non-IND stakeholders. FDA states that the guidance will be updated as communication practices evolve.
Source: FDA
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
